Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

被引：2

作者：

Karimi, Yasmin H. ^{[1
]}

Jain, Nitin ^{[2
]}

Green, Margaret ^{[1
]}

Godley, Lucy A. ^{[1
]}

Weiner, Howie Lawrence ^{[1
]}

Malnassy, Gregory ^{[1
]}

Fulton, Noreen ^{[1
]}

Artz, Andrew ^{[1
]}

Liu, Hongtao ^{[1
]}

Thirman, Michael J. ^{[1
]}

Daunov, Michael ^{[1
]}

Larson, Richard A. ^{[1
]}

Stock, Wendy ^{[1
]}

Odenike, Olatoyosi ^{[1
]}

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.118.118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] A SINGLE INSTITUTION EXPERIENCE OF INDUCTION WITH HIGH DOSE CYTARABINE AND MITOXANTRONE FOR HIGH RISK ELDERLY ACUTE MYELOID LEUKEMIA (AML) PATIENTS INCLUDING AGE > 70
Ramanathan, M.
Cerny, J.
Raffel, G.
Walsh, W.
Bednarik, J.
Fortier, N.
Kroll-Desrosiers, A.
Woda, B.
Miron, P.
Nath, R.
HAEMATOLOGICA, 2012, 97 : 272 - 273
[32] High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?
Schwarer, Anthony P.
Wight, Joel
Jackson, Kathryn
Beligaswatte, Ashanka Mahilal
Butler, Jason P.
Kennedy, Glen
Martin, Louisa
Lewis, Ian D.
Hiwase, Devendra
Zantomio, Daniela
He, Simon Z.
Grigg, Andrew
Morris, Kirk
Mollee, Peter
Marlton, Paula
BLOOD, 2016, 128 (22)
[33] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Lowenberg, Bob
BLOOD, 2013, 121 (01) : 26 - 28
[34] HIGH-DOSE METHYLPREDNISOLONE FOR REMISSION INDUCTION IN HYPOPLASTIC ACUTE MYELOID-LEUKEMIA
HICSONMEZ, G
CETIN, M
TUNCER, MA
GUMRUK, F
OZBEK, N
KARA, A
GURGEY, A
EUROPEAN JOURNAL OF HAEMATOLOGY, 1995, 54 (02) : 125 - 126
[35] HIGH-DOSE CYTOSINE-ARABINOSIDE AND MITOXANTRONE IN HIGH-RISK ACUTE NONLYMPHOBLASTIC LEUKEMIA
SANZ, MA
MARTINEZ, J
BORREGO, D
MARTINARAGONES, G
LORENZO, I
SANZ, G
SAYAS, MJ
JARQUE, I
PASTOR, E
RAFECAS, J
SEMINARS IN ONCOLOGY, 1987, 14 (02) : 18 - 20
[36] Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia
Lei, Meiqing
Liu, Limin
Wang, Zhiming
Wu, Depei
INDIAN JOURNAL OF CANCER, 2019, 56 (02) : 167 - 172
[37] Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).
Veltri, Lauren Westfall
Anders, Brandi
Kanate, Abraham Sebastian
Shillingburg, Alexandra
Craig, Michael D.
Cumpston, Aaron
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[38] Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone:: Results of study Acute Myeloid Leukemia -: Berlin-Frankfurt-Munster 93
Creutzig, U
Ritter, J
Zimmermann, M
Reinhardt, D
Hermann, J
Berthold, F
Henze, G
Jürgens, H
Kabisch, H
Havers, W
Reiter, A
Kluba, U
Niggli, F
Gadner, H
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2705 - 2713
[39] Timed sequential therapy with high-dose cytarabine and mitoxantrone as an induction regimen for acute myeloid leukemia:An update on adverse events.
Richardson, Kristin J.
Kollipara, Revathi
Katz, Deborah Ann
Hoyt, Maura
Gallas, Kirstin
Venugopal, Parameswaran
Larson, Melissa L.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[40] Idarubicin high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia.
Eisen, T
Powles, R
Singhal, S
Middleton, G
Treleaven, J
Mehta, J
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 253 - 253

← 1 2 3 4 5 →